- Home
- Publications
- Publication Search
- Publication Details
Title
The Relationship of Asthma Biologics to Remission for Asthma
Authors
Keywords
-
Journal
Journal of Allergy and Clinical Immunology-In Practice
Volume 9, Issue 3, Pages 1090-1098
Publisher
Elsevier BV
Online
2020-10-29
DOI
10.1016/j.jaip.2020.10.035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development and initial validation of the Asthma Severity Scoring System (ASSESS)
- (2019) Anne M. Fitzpatrick et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- An expert consensus framework for asthma remission as a treatment goal
- (2019) Andrew Menzies-Gow et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical predictors of remission and persistence of adult-onset asthma
- (2018) Guus A. Westerhof et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Asthma across the lifespan: Time for a paradigm shift
- (2018) Stanley J. Szefler JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
- (2018) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
- (2018) Mario Castro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
- (2018) J Mark FitzGerald et al. Lancet Respiratory Medicine
- Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
- (2018) Thomas B. Casale et al. Journal of Allergy and Clinical Immunology-In Practice
- Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
- (2018) Sumita Khatri et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma
- (2016) Michael J. McGeachie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting key proximal drivers of type 2 inflammation in disease
- (2015) Namita A. Gandhi et al. NATURE REVIEWS DRUG DISCOVERY
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma
- (2013) Michael C. Peters et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Remission and Persistence of Asthma Followed From 7 to 19 Years of Age
- (2013) M. Andersson et al. PEDIATRICS
- Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents
- (2012) Jeremy J. Wildfire et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- (2011) David T. Felson et al. ARTHRITIS AND RHEUMATISM
- Safety and tolerability of omalizumab
- (2009) J. Corren et al. CLINICAL AND EXPERIMENTAL ALLERGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started